Significant readouts for small players
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea
The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
